| Knowledge4COVID-19

Property	Value
is ?:annotates of	<https://research.tib.eu/covid-19/entity/34411984_HAS_TOPIC_C0026769> <https://research.tib.eu/covid-19/entity/34411984_HAS_TOPIC_C0086418> <https://research.tib.eu/covid-19/entity/34411984_HAS_TOPIC_C0751324> <https://research.tib.eu/covid-19/entity/34411984_HAS_TOPIC_C1615608> <https://research.tib.eu/covid-19/entity/34411984_HAS_TOPIC_C1882138> <https://research.tib.eu/covid-19/entity/34411984_HAS_TOPIC_C2605279> <https://research.tib.eu/covid-19/entity/34411984_HAS_TOPIC_C2605280> <https://research.tib.eu/covid-19/entity/34411984_HAS_TOPIC_C2985546> <https://research.tib.eu/covid-19/entity/34411984_HAS_TOPIC_C4325109> <https://research.tib.eu/covid-19/entity/34411984_HAS_TOPIC_C5203670> <https://research.tib.eu/covid-19/entity/34411984_HAS_TOPIC_C5203676> <https://research.tib.eu/covid-19/entity/34411984_HAS_TOPIC_C5227786> <https://research.tib.eu/covid-19/entity/34411984_HAS_TOPIC_C5392141>
?:authorAffiliation	[\'F. Hoffmann-La Roche Ltd, Basel, Switzerland. Electronic address: rosetta.pedotti@roche.com.\', \'F. Hoffmann-La Roche Ltd, Basel, Switzerland.\']
?:citedBy	-1
?:creator	<https://research.tib.eu/covid-19/entity/Jessop_Nikki> <https://research.tib.eu/covid-19/entity/Muros-Le_Rouzic_Erwan> <https://research.tib.eu/covid-19/entity/Pedotti_Rosetta> <https://research.tib.eu/covid-19/entity/Raposo_Catarina> <https://research.tib.eu/covid-19/entity/Schippling_Sven>
?:doi	S2211-0348(21)00470-310.1016/j.msard.2021.103203
?:doi	<https://research.tib.eu/covid-19/entity/S2211-0348%2821%2900470-310.1016/j.msard.2021.103203>
?:hasPublicationType	<https://research.tib.eu/covid-19/entity/Letter>
?:journal	Multiple sclerosis and related disorders
is ?:pmid of	<https://research.tib.eu/covid-19/entity/34411984>
?:pmid	<https://research.tib.eu/covid-19/entity/34411984>
?:pmid	34411984
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/Covid-19>
?:rankingScore_SJR	1.123
?:rankingScore_hIndex	18
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/C1825598_INHIBITS_C1882138>
?:title	Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab.
?:type	<https://research.tib.eu/covid-19/vocab/Publication> <https://research.tib.eu/covid-19/vocab/Publication_Author>
?:year	2021

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/34411984>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/34411984>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all